Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 200

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

COMPASS Pathways and partners launch The Centre for Mental Health Research...

Awakn Life Sciences Announces Closing of Private Placement

PT303 – Adam Bramlage – Cannabis, Microdosing, and Our Evolutionary Connection...

Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

PT302 – Dr. Adele Lafrance – Vital Psychedelic Conversations

How Can We Apply Harm Reduction to HPPD?

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London...

Green Market Report – Are Psychedelics Leaving Minorities Behind?

MINDCURE Provides Update on Strategic Review

Nova Mentis Announces Closing of Non-Brokered Financing

Load more

EDITOR PICKS

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets...

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©